Lessons from international experience in controlling pharmaceutical expenditure .1. Influencing patients

被引:43
作者
Freemantle, N
Bloor, K
机构
[1] UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND
[2] UNIV YORK,DEPT HLTH SCI & CLIN EVALUAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND
关键词
D O I
10.1136/bmj.312.7044.1469
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This is the first of three papers to review international policies to control spending on drugs and improve the efficiency of drug use. Policies can target three main groups: patients, prescribing doctors, and the drugs industry, In this paper we examine policies aimed at patients, particularly restrictions on reimbursement (such as prescription charges), Rigorous experimental and quasi-experimental studies suggest that policies to limit the level of reimbursement of drugs reduce the use of essential as well as non-essential drugs and may do more harm than good.
引用
收藏
页码:1469 / 1471
页数:3
相关论文
共 18 条
[1]  
BARER M, 1979, CONTROLLING HLTH CAR
[2]  
*COCHR COLL EFF PR, 1995, COCHR DAT SYST REV
[3]  
Day, 1979, QUASIEXPERIMENTATION, V351
[4]  
Department of Health, 1994, HLTH PERS SOC SERV S
[5]  
HARRIS BL, 1990, MED CARE, V28, P901
[6]  
HINCHCLIFFE H, 1959, FINAL REPORT COMMITT
[7]  
LAVERS RJ, 1989, APPL ECON, V21, P1043
[8]  
OBRIEN B, 1982, TIMES HLTH S 0119, P1
[9]  
*OFF HLTH EC, 1995, OHE COMP HLTH STAT
[10]   EXAMINING PRODUCT RISK IN CONTEXT - MARKET WITHDRAWAL OF ZOMEPIRAC AS A CASE-STUDY [J].
ROSSDEGNAN, D ;
SOUMERAI, SB ;
FORTESS, EE ;
GURWITZ, JH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (16) :1937-1942